Latest Information Update: 05 Dec 2006
At a glance
- Originator ZymoGenetics
- Mechanism of Action Platelet-derived growth factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Liver cirrhosis
Most Recent Events
- 06 Aug 2002 Preclinical trials for Cirrhosis in the USA (unspecified route)